X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Reviva intends to use the net proceeds to fund research and development activities, including the registrational Phase 3 RECOVER-2 trial evaluating RP5063 (brilaroxazine) in schizophrenia.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 29, 2024
Details:
The gross proceeds from the offering will be used to fund research and development activities, including the late-stage product RP5063 (brilaroxazine), which is evaluated for treating schizophrenia.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 28, 2024
Details:
RP5063 (brilaroxazine), an atypical antipsychotic with potent affinity & selectivity against key serotonin & dopamine receptors, is being developed for the treatment of schizophrenia.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2024
Details:
RP5063 (brilaroxazine), an atypical antipsychotic new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors, is being developed for the treatment of schizophrenia.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
The net proceeds will fund research and development activities, including the registrational Phase 3 RECOVER-2 trial evaluating RP5063 (brilaroxazine), an in-house discovered new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors.
Lead Product(s): Brilaroxazine
Therapeutic Area: Dermatology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 20, 2023
Details:
The net proceeds will fund research and development activities, including the registrational Phase 3 RECOVER-2 trial evaluating RP5063 (brilaroxazine), an in-house discovered new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors.
Lead Product(s): Brilaroxazine
Therapeutic Area: Dermatology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 16, 2023
Details:
RP5063 (brilaroxazine), an atypical antipsychotic new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors, is being developed for the treatment of schizophrenia.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
RP5063 (brilaroxazine), an atypical antipsychotic new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors, is being developed for the treatment of schizophrenia.
Lead Product(s): Brilaroxazine
Therapeutic Area: Dermatology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Details:
RP5063 (brilaroxazine) is selectivity against key serotonin and dopamine receptors implicated in schizophrenia and its comorbid symptoms. In a multinational, multicenter, double-blind Phase 2 study in 234 patients with acute schizophrenia or schizoaffective disorder.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2023
Details:
RP5063 (brilaroxazine), an atypical antipsychotic new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors, is being developed for the treatment of schizophrenia.
Lead Product(s): Brilaroxazine
Therapeutic Area: Psychiatry/Psychology Product Name: RP5063
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
